Matthew Meyerson began his research group at Dana-Farber Cancer Institute in 1998 with the goal of using genomic approaches to understand the causes of human cancer, with a focus on lung cancer, and to apply this new understanding to the development of effective treatments that kill cancer cells while sparing healthy cells.